Paula Marie Ladwig
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Paula Marie Ladwig has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Maria Alice Vieira Willrich
Department of Laboratory Medicine and Pathology, Mayo Clinic , Rochester, MN
4 shared publications - David Murray
Department of Laboratory Medicine and Pathology, Mayo Clinic , Rochester, MN
2 shared publications - Melissa R. Snyder
Department of Laboratory Medicine and Pathology, Division of Clinical Biochemistry and Immunology, Mayo Clinic , Rochester, MN
2 shared publications Abdulrahman Saadalla
Mayo Clinic, Rochester, Minnesota, United States
1 shared publication- Adam J. McShane
Department of Pathology and Laboratory Medicine, Cleveland Clinic , Cleveland, OH
1 shared publication Alicia Algeciras-Schimnich
Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA
1 shared publication
Latest Publications
- Open Access
- 28 May 2026
- Published by Oxford University Press (OUP) in The Journal of Applied Laboratory Medicine
- Vol. 11 (5) , 1278-1281
Reference Material Choice Affects LC-MS/MS Infliximab Quantitation
- 28 May 2026
- Published by Oxford University Press (OUP) in The Journal of Applied Laboratory Medicine
- Vol. 11 (5) , 1278-1281
Open AccessReference Material Choice Affects LC-MS/MS Infliximab Quantitation
- 19 December 2023
- Published by Springer Nature
- Vol. 2750, 95-106
Alpha-1-Antitrypsin (A1AT) Proteotyping by LC-MS/MS
The diagnosis of alpha-1-antitrypsin (A1AT) deficiency is established by quantitation of protein concentration in serum (immunoassay) followed by determination of specific allelic variants by phenotyping (isoelectric focusing (IEF) gel electrophoresis) and/or allele-specific genotyping. Various phenotyping and genotyping methodologies are available, and each has their own advantages and disadvantages. As an alternative, mass spectrometry is emerging as a powerful tool in the identification and quantitation of proteins and peptides. The method described here, referred to as proteotyping, is a proteomic method using trypsin digestion and tandem mass spectrometry that detects the most common deficiency alleles, S and Z, associated with A1AT deficiency. This qualitative mass spectrometry method is based on the principle that the S and Z mutations lead to amino acid changes which result in a change in the mass of the A1AT protein. When the A1AT protein is proteolytically digested, multiple peptides are generated, two of which include the sites of the S and Z mutations, respectively. Peptides generated from wild-type A1AT (M alleles) differ in sequence and mass from peptides generated from the S and Z alleles at these two specific locations. The mass difference allows for differentiation of S and Z peptides, representing the deficiency alleles, from non-S and non-Z peptides, representing the wild-type alleles (M). Interpretation of the peptide patterns in conjunction with A1AT quantitation by immunoassay allows for an accurate assessment for the presence of deficiency alleles in the majority of patients. Key words Alpha-1-antitrypsin Tryptic digestion Mass spectrometry Tandem mass spectrometry Liquid chromatography Targeted proteomics Multiple reaction monitoring Single nucleotide polymorphisms Protein variants
- 19 December 2023
- Published by Springer Nature
- Vol. 2750, 95-106
Alpha-1-Antitrypsin (A1AT) Proteotyping by LC-MS/MS
The diagnosis of alpha-1-antitrypsin (A1AT) deficiency is established by quantitation of protein concentration in serum (immunoassay) followed by determination of specific allelic variants by phenotyping (isoelectric focusing (IEF) gel electrophoresis) and/or allele-specific genotyping. Various phenotyping and genotyping methodologies are available, and each has their own advantages and disadvantages. As an alternative, mass spectrometry is emerging as a powerful tool in the identification and quantitation of proteins and peptides. The method described here, referred to as proteotyping, is a proteomic method using trypsin digestion and tandem mass spectrometry that detects the most common deficiency alleles, S and Z, associated with A1AT deficiency. This qualitative mass spectrometry method is based on the principle that the S and Z mutations lead to amino acid changes which result in a change in the mass of the A1AT protein. When the A1AT protein is proteolytically digested, multiple peptides are generated, two of which include the sites of the S and Z mutations, respectively. Peptides generated from wild-type A1AT (M alleles) differ in sequence and mass from peptides generated from the S and Z alleles at these two specific locations. The mass difference allows for differentiation of S and Z peptides, representing the deficiency alleles, from non-S and non-Z peptides, representing the wild-type alleles (M). Interpretation of the peptide patterns in conjunction with A1AT quantitation by immunoassay allows for an accurate assessment for the presence of deficiency alleles in the majority of patients. Key words Alpha-1-antitrypsin Tryptic digestion Mass spectrometry Tandem mass spectrometry Liquid chromatography Targeted proteomics Multiple reaction monitoring Single nucleotide polymorphisms Protein variants
- 15 November 2023
- Published by Elsevier in Clinical Biochemistry
- Vol. 121-122, 110685
Lack of observed interference by therapeutic monoclonal antibodies in select commonly utilized immunoassays
- 15 November 2023
- Published by Elsevier in Clinical Biochemistry
- Vol. 121-122, 110685
Lack of observed interference by therapeutic monoclonal antibodies in select commonly utilized immunoassays
- Open Access
- 26 July 2023
- Published by Elsevier in Clinical Biochemistry
- Vol. 119, 110618
Outcomes of Infliximab-Treated inflammatory bowel disease patients undergoing therapeutic drug monitoring with two different assays
- 26 July 2023
- Published by Elsevier in Clinical Biochemistry
- Vol. 119, 110618
Open AccessOutcomes of Infliximab-Treated inflammatory bowel disease patients undergoing therapeutic drug monitoring with two different assays
- 13 September 2022
- Published by Elsevier in Clinical Biochemistry
- Vol. 109-110, 11-16
Characterizing M-protein light chain glycosylation via mass spectrometry
- 13 September 2022
- Published by Elsevier in Clinical Biochemistry
- Vol. 109-110, 11-16
Characterizing M-protein light chain glycosylation via mass spectrometry
- 3 March 2022
- Published by Oxford University Press (OUP) in The Journal of Applied Laboratory Medicine
- Vol. 7 (3) , 815-817
Flawed Critique of CLSI Guideline EP05-A2
- 3 March 2022
- Published by Oxford University Press (OUP) in The Journal of Applied Laboratory Medicine
- Vol. 7 (3) , 815-817
Flawed Critique of CLSI Guideline EP05-A2
- Open Access
- 12 August 2021
- Published by Stanford University Press in Journal of Mass Spectrometry and Advances in the Clinical Lab
- Vol. 21, 10-18
Ravulizumab: Characterization and quantitation of a new C5 inhibitor using isotype specific affinity purification and high-resolution mass spectrometry
Ravulizumab (RAVUL) is a new complement inhibitor, with a difference of 4 amino acids in the heavy chain from a predecessor compound, eculizumab (ECUL). First, to utilize mass spectrometry (MS) to characterize RAVUL and verify differences from its predecessor and, second, to validate and implement a lab developed test (LDT) for RAVUL that will allow for quantitative therapeutic monitoring. A time-of-flight mass spectrometer (TOF-MS) was used to characterize and differentiate the molecular weight differences between RAVUL and ECUL by both digest and reduction experiments. In parallel, an LDT for RAVUL was validated and implemented utilizing IgG4 enrichment with light chain detection and quantitation on a high throughput orbitrap MS platform. The TOF-MS platform allowed for the mass difference between RAVUL and ECUL to be verified along with providing a proof of concept for a new intact protein quantitation software. An LDT on an orbitrap MS was validated and implemented using intact light chain quantitation, with the limitation that it cannot differentiate between ECUL and RAVUL. The LDT has an analytical measuring range from 5 to 600 mcg/mL, inter-assay imprecision of ≤13% CV (n = 13) and accuracy with <4% error from expected values (n = 20). The TOF-MS is a versatile development platform that can be used to characterize and verify the molecular weight differences between the ECUL and RAVUL heavy chains. Routine laboratory testing for RAVUL was viable using an orbitrap-MS to quantitate using the mass of the intact light chain. These two platforms, combined, provide incomparable value in development of LDTs for the clinical laboratory.
- 12 August 2021
- Published by Stanford University Press in Journal of Mass Spectrometry and Advances in the Clinical Lab
- Vol. 21, 10-18
Open AccessRavulizumab: Characterization and quantitation of a new C5 inhibitor using isotype specific affinity purification and high-resolution mass spectrometry
Ravulizumab (RAVUL) is a new complement inhibitor, with a difference of 4 amino acids in the heavy chain from a predecessor compound, eculizumab (ECUL). First, to utilize mass spectrometry (MS) to characterize RAVUL and verify differences from its predecessor and, second, to validate and implement a lab developed test (LDT) for RAVUL that will allow for quantitative therapeutic monitoring. A time-of-flight mass spectrometer (TOF-MS) was used to characterize and differentiate the molecular weight differences between RAVUL and ECUL by both digest and reduction experiments. In parallel, an LDT for RAVUL was validated and implemented utilizing IgG4 enrichment with light chain detection and quantitation on a high throughput orbitrap MS platform. The TOF-MS platform allowed for the mass difference between RAVUL and ECUL to be verified along with providing a proof of concept for a new intact protein quantitation software. An LDT on an orbitrap MS was validated and implemented using intact light chain quantitation, with the limitation that it cannot differentiate between ECUL and RAVUL. The LDT has an analytical measuring range from 5 to 600 mcg/mL, inter-assay imprecision of ≤13% CV (n = 13) and accuracy with <4% error from expected values (n = 20). The TOF-MS is a versatile development platform that can be used to characterize and verify the molecular weight differences between the ECUL and RAVUL heavy chains. Routine laboratory testing for RAVUL was viable using an orbitrap-MS to quantitate using the mass of the intact light chain. These two platforms, combined, provide incomparable value in development of LDTs for the clinical laboratory.
- 22 October 2020
- Published by American Society of Hematology in Blood
- Vol. 136 (17) , 1988-1992
Sialic acid–bearing paraproteins are implicated in heparin-like coagulopathy in patients with myeloma
- 22 October 2020
- Published by American Society of Hematology in Blood
- Vol. 136 (17) , 1988-1992
Sialic acid–bearing paraproteins are implicated in heparin-like coagulopathy in patients with myeloma
- Open Access
- 1 April 2003
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 49 (4) , 664-666
Capillary Electrophoresis Method to Measure p-Aminohippuric Acid in Urine and Plasma for the Assessment of Renal Plasma Flow
- 1 April 2003
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 49 (4) , 664-666
Open AccessCapillary Electrophoresis Method to Measure p-Aminohippuric Acid in Urine and Plasma for the Assessment of Renal Plasma Flow